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remains an open question. The study by Tice et 
al.,1 which is based on the findings of the Breast 
Cancer Surveillance Consortium, showed consid-
erable overlap in the risk estimates for women 
with atypical hyperplasia and the four density 
categories. It was only women with atypical hy-
perplasia and extremely dense breast tissue (12% 
of the entire group with atypical hyperplasia) 
whose risk did not overlap completely with the 
fatty-breast category; this group with high-densi-
ty tissue had a substantially higher risk of breast 
cancer.
In response to Reimers et al.: their overall 
cohort consists of women with various risk fea-
tures, especially a family history of breast can-
cer.2 In their most recent article on density, all 
benign breast disease is grouped together.3 In 
this letter, they refer to an unspecified number 
of women in a subgroup with atypical hyper-
plasia and suggest that such women with low 
breast density may not be at increased risk for 
breast cancer. They do not state how they han-
dled the effect of age on density and breast-
cancer risk.
To follow up on the question posed in both 
letters, we identified a subgroup of women in 
our atypical-hyperplasia cohort for whom we had 
readily attainable density information (Table 1).4 
Although numbers are limited at this time, we 
see no significant difference in risk according 
to breast-density measurement in women with 
atypical hyperplasia, and thus suggest that this 
important question merits additional investi-
gation.
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Case 39-2014: A Girl with Crohn’s Disease and Pulmonary 
Nodules
To the Editor: Nelson et al. (Dec. 18 issue)1 re-
port the case of a 9-year-old girl with familial 
Crohn’s disease and pulmonary nodules. Chronic 
granulomatous disease was considered and re-
jected by El Saleeby. We believe this rejection was 
based on insufficient data. Chronic granuloma-
tous disease can be ruled out only by the mea-
surement of reactive oxygen species (ROS) produc-
tion by granulocytes. Testing for ROS production, 
which was not performed, could have had major 
clinical consequences in this patient, because 
Crohn’s disease is clinically and histologically in-
distinguishable from colitis related to chronic 
granulomatous disease,2,3 and in patients with 
chronic granulomatous disease, it would be es-
sential to rule out infections with pathogens 
such as burkholderia, nocardia, granulibacter, 
and aspergillus before initiating immunosup-
pressive therapy.
Anti–tumor necrosis factor (TNF) treatment 
in patients with chronic granulomatous disease 
is associated with increased mortality.4 There-
fore, testing ROS production to rule out this 
disease and evaluating the patient for opportun-
istic infections are needed before initiating anti-
TNF treatment in cases such as the reported 
one. Finally, the exclusion of obvious mutations 
in the NADPH-oxidase complex that cause chron-
ic granulomatous disease and NOD2 (indicating 
Crohn’s disease and Blau’s syndrome) would be 
equally useful before performing whole-exome 
sequencing.
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The Discussants Reply: Van de Veerdonk and 
colleagues correctly note that chronic granulo-
matous disease cannot be ruled out without mea-
suring granulocyte production of ROS. However, 
in our opinion, such testing was not necessary in 
this case.
Many features of chronic granulomatous dis-
ease were incongruent with this patient’s history 
and presentation. Chronic granulomatous dis-
ease is a rare condition with significant male 
predominance.1 Although not universal, a large 
majority of patients with this disease have a his-
tory of chronic or recurrent infections,1 such as 
pneumonias and abscesses, neither of which were 
present.
Gastrointestinal manifestations rarely pre-
cede a diagnosis of chronic granulomatous dis-
ease1 and are less likely to occur with autosomal 
recessive inheritance of the disease. This patient 
is female, and her histologic examination re-
vealed chronic colitis and poorly formed granu-
lomas, which better support a diagnosis of Crohn’s 
disease. In contrast, the histologic examination 
of colitis in chronic granulomatous disease of-
ten lacks chronicity and shows more sharply 
demarcated granulomas.2 Furthermore, routine 
screening for chronic granulomatous disease in 
patients with inflammatory bowel disease has 
not been found to be informative.3
Owing to the complexity of this case, bron-
choalveolar lavage was completed before anti-
TNF therapy was initiated. Testing was negative 
for sentinel organisms indicative of chronic 
granulomatous disease.
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More on Remission of Recalcitrant Dermatomyositis Treated  
with Ruxolitinib
To the Editor: In response to the letter from 
Hornung et al. (Dec. 25 issue)1: we would like to 
point out some concerns that we think are rele-
vant. Recalcitrant dermatomyositis is a challeng-
ing condition for clinicians, so the efficacy of a 
new drug is worthy. Nevertheless, the clinical 
situation reported by the authors should be rec-
ognized as a cancer-associated dermatomyositis 
(hematologic neoplasm occurring within 3 years 
after the diagnosis of dermatomyositis). This 
type of dermatomyositis is characterized by a 
temporal relationship between myositis and can-
cer. So in this patient, the improvement that was 
seen after ruxolitinib therapy could be due to the 
improvement in the hematologic cancer and sub-
sequently the associated dermatomyositis, rather 
than to improvement in the dermatomyositis it-
self. It would be interesting to know whether the 
authors measured the levels of antibody against 
transcriptional intermediary factor 1 γ (TIF1γ, 
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